% 0期刊文章%一个胡安·巴斯克斯Shubham Misra % %一个卢卡斯Scardua席尔瓦Ece Eldem % %一个萨巴Mohidat % % l . Brian Hickman Erum汗%一克拉丽莎Yasuda梅丽莎Funaro % %一个作者Nishant Scott Kasner大卫Liebeskind % % k Mishra % T中风后癫痫发作患者的死亡率和功能结果:系统回顾和荟萃分析(S45.006) % D R 10.1212 / WNL 2023%。0000000000203419 % J首页神经病学% P V 100% N 17补充2% 3645% X目的:进行荟萃分析的数据,全面调查临床和功能结果发表在中风后癫痫(PSE)患者。背景:关键是强调对病人结果PSE的负担。而PSE据报道在中风患者恶化的结果,公布的数据是不确定的。设计/方法:我们使用Covidence进行文献检索的研究直到1 - 3月- 2022年出版。我们使用乔安娜·布里格斯研究所队列研究的工具来评估偏差的风险。我们的结果的措施包括死亡率和糟糕的结果(兰金量表得分3 - 6)。我们报告比值比(或)和95%置信区间(CI)使用随机效应分析。发表偏倚评估使用症的测试。我们在4.2.0 R版本进行了统计分析。(普洛斯彼罗ID: CRD42022308648)结果:我们筛选3721研究,其中包括71篇文章(N = 29759 PSE患者;17日,42083名患者没有PSE)。 Articles reported 3938 early and 13,067 late seizures; 12,754 seizures were not classified as early/late. Risk of bias was high in two studies, moderate in 36 and low in 33. PSE was associated with greater odds of mortality (OR 2.09; CI 1.78–2.45; N= 52 studies) and poor outcomes (OR 2.39; CI 1.91–3.00; N= 19 studies). In subgroup analyses, post-ischemic stroke epilepsy was associated with mortality (OR 2.31; CI 1.88–2.83) and poor outcome (OR 2.60; CI 1.91–3.52). Post-hemorrhagic stroke epilepsy showed consistently significant OR for the poor outcome (OR 2.04; CI 1.33–3.13) but failed to reach statistical significance for mortality (OR 1.29; CI 0.96–1.74). No significant publication bias was observed for mortality (p=0.93) and poor outcome (p=0.17).Conclusions: Our meta-analysis suggests that PSE is associated with a doubled risk of death and severe disability. Prevention of PSE should be a high research priority. The role of stroke severity or lesion volume also requires further study.Disclosure: Mr. Misra has nothing to disclose. Juan Vazquez, MD has nothing to disclose. Ms. Eldem has nothing to disclose. Lucas Silva has nothing to disclose. Dr. Mohadat has nothing to disclose. Dr. Hickman has nothing to disclose. Ms. Khan has nothing to disclose. Mrs. Funaro has nothing to disclose. Clarissa Yasuda has nothing to disclose. Dr. Liebeskind has received research support from Cerenovus. Dr. Liebeskind has received research support from Genentech . Dr. Liebeskind has received research support from Medtronic. Dr. Liebeskind has received research support from Stryker. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Diamedica. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Javelin. Dr. Kasner has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Kasner has received research support from Bristol-Myers Squibb. The institution of Dr. Kasner has received research support from Medtronic. The institution of Dr. Kasner has received research support from WL Gore. Dr. Mishra has nothing to disclose. %U